Biotechnology company Chimeron Bio announced on Monday that it entered into a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to evaluate the potential of its lead vaccine candidate CB-106 for COVID-19.
As part of the collaboration with George Mason University, Chimeron's CB-106's preliminary data demonstrated positive results in pre-clinical models with nanogram quantities of RNA, a dose advantage over other RNA based technologies.
CB-106 reportedly delivers the Spike gene as self-amplifying mRNA, added Chimeron.
Pursuant to the agreement, Chimeron Bio will utilize the pre-clinical services programme offered by the NIAID.
In conjunction with the partnership, Chimeron Bio will provide the vaccine candidate to test in the hamster model of COVID-19, which has been used for the assessment of other COVID-19 vaccines.
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children